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Synaptic NMDA receptor activation stimulates
alpha-secretase amyloid precursor protein processing and
inhibits amyloid-beta production
Abstract
Altered amyloid precursor protein (APP) processing leading to increased production and
oligomerization of Abeta may contribute to Alzheimer's disease (AD). Understanding how
APP processing is regulated under physiological conditions may provide new insights into
AD pathogenesis. Recent reports demonstrate that excitatory neural activity regulates APP
metabolism and Abeta levels, although understanding of the molecular mechanisms involved
is incomplete. We have investigated whether NMDA receptor activity regulates APP
metabolism in primary cultured cortical neurons. We report that a pool of APP is localized to
the postsynaptic compartment in cortical neurons and observed partial overlap of APP with
both NR1 and PSD-95. NMDA receptor stimulation increased nonamyloidogenic
alpha-secretase-mediated APP processing, as measured by a 2.5-fold increase in cellular
alpha-C-terminal fragment (C83) levels after glutamate or NMDA treatment. This increase was
blocked by the NMDA receptor antagonists d-AP5 and MK801 but not by the AMPA receptor
antagonist CNQX or the L-type calcium channel blocker nifedipine, was prevented by
chelation of extracellular calcium, and was blocked by the alpha-secretase inhibitor TAPI-1.
Cotreatment of cortical neurons with bicuculline and 4-AP, which stimulates glutamate release
and activates synaptic NMDA receptors, evoked an MK801-sensitive increase in C83 levels.
Furthermore, NMDA receptor stimulation caused a twofold increase in the amount of soluble
APP detected in the neuronal culture medium. Finally, NMDA receptor activity inhibited both
Abeta1-40 release and Gal4-dependent luciferase activity induced by
beta-gamma-secretase-mediated cleavage of an APP-Gal4 fusion protein. Altogether, these
data suggest that calcium influx through synaptic NMDA receptors promotes
nonamyloidogenic alpha-secretase-mediated APP processing.
Neurobiology of Disease
Synaptic NMDA Receptor Activation Stimulates -Secretase
Amyloid Precursor Protein Processing and Inhibits
Amyloid- Production
Sarah E. Hoey, Robert J. Williams, andMichael S. Perkinton
King’s College London, Wolfson Centre for Age-Related Diseases, London SE1 1UL, United Kingdom
Altered amyloid precursor protein (APP) processing leading to increased production and oligomerization of A may contribute to
Alzheimer’s disease (AD).UnderstandinghowAPPprocessing is regulatedunder physiological conditionsmayprovidenew insights into
AD pathogenesis. Recent reports demonstrate that excitatory neural activity regulates APP metabolism and A levels, although under-
standing of the molecular mechanisms involved is incomplete. We have investigated whether NMDA receptor activity regulates APP
metabolism in primary cultured cortical neurons. We report that a pool of APP is localized to the postsynaptic compartment in cortical
neurons and observed partial overlap of APP with both NR1 and PSD-95. NMDA receptor stimulation increased nonamyloidogenic
-secretase-mediated APP processing, asmeasured by a 2.5-fold increase in cellular-C-terminal fragment (C83) levels after glutamate
or NMDA treatment. This increase was blocked by the NMDA receptor antagonists D-AP5 and MK801 but not by the AMPA receptor
antagonist CNQXor the L-type calcium channel blocker nifedipine, was prevented by chelation of extracellular calcium, andwas blocked
by the-secretase inhibitor TAPI-1. Cotreatment of cortical neurons with bicuculline and 4-AP, which stimulates glutamate release and
activates synaptic NMDA receptors, evoked anMK801-sensitive increase in C83 levels. Furthermore, NMDA receptor stimulation caused
a twofold increase in the amount of solubleAPPdetected in the neuronal culturemedium. Finally, NMDAreceptor activity inhibited both
A1-40 release and Gal4-dependent luciferase activity induced by --secretase-mediated cleavage of an APP-Gal4 fusion protein.
Altogether, these data suggest that calcium influx through synapticNMDA receptors promotes nonamyloidogenic-secretase-mediated
APP processing.
Introduction
Alzheimer’s disease (AD) is a progressive dementia characterized
by extracellular deposits of amyloid  (A) in senile plaques and
intracellular neurofibrillary tangles comprising hyperphospho-
rylated tau assembled into paired helical filaments (Selkoe, 2001).
In the early stages of AD, the most common symptom is short-
term memory loss, which is thought to result from a failure of
specific neuronal networks of the hippocampus and cortex that
are involved in memory functions (Selkoe, 2002) and use gluta-
mate as the major excitatory neurotransmitter (Ozawa et al.,
1998). A recently updated version of the amyloid cascade hypoth-
esis of AD proposes that soluble A oligomers are responsible for
the early cognitive decline inAD (Walsh and Selkoe, 2007), which
emerged as a result of experiments showing that soluble A oli-
gomers block learning and memory processes in rodents (Lam-
bert et al., 1998; Walsh et al., 2002; Wang et al., 2002; Lesne´ et al.,
2006). It has been proposed that AD may be an A-mediated
synaptic failure (Selkoe, 2002; Marcello et al., 2008), and experi-
mental evidence suggests that excitatory glutamatergic synapses
may be the major target of soluble A oligomers (Lacor et al.,
2004, 2007). Furthermore, soluble A oligomers have been re-
ported to disrupt postsynaptic glutamate receptor trafficking and
signaling (Kamenetz et al., 2003; Wang et al., 2004; Roselli et al.,
2005; Snyder et al., 2005; Hsieh et al., 2006; Shankar et al., 2007;
Abbott et al., 2008).
A is produced when the amyloid precursor protein (APP) is
cleaved by- and-secretase, but there is also a non-A-forming
pathway in cells involving-secretase (Wilquet andDe Strooper,
2004). Within the brain, A is found in its normal soluble form
throughout life, and evidence suggests that APP metabolism and
A levels are closely correlated with neural activity in animals
(Fazeli et al., 1994; Cirrito et al., 2005, 2008) and humans (Buck-
ner et al., 2005). It has recently been demonstrated that synaptic
activity modulates a readily releasable pool of A from nerve
terminals (Cirrito et al., 2005). Alternatively, electrical depolar-
ization, protein kinase C activation, and stimulation of musca-
rinic M1 acetylcholine receptors or mGluR1 glutamate recep-
tors have all been reported to promote nonamyloidogenic
-secretase cleavage of APP (Nitsch et al., 1992, 1993, 1997, 2000;
Caputi et al., 1997; Caccamo et al., 2006). In primary cultures of
hippocampal neurons, stimulation of NMDA receptors increases
trafficking of the candidate -secretase ADAM10 to the postsyn-
aptic membrane (Marcello et al., 2007); thus, NMDA receptor
activity may also enhance nonamyloidogenic APP processing.
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However, it has previously been reported that chronic NMDA
receptor activation decreases-secretase-mediated APP process-
ing and increases A production in cultured cortical neurons
(Lesne´ et al., 2005).
We have investigated whether NMDA receptor activity regu-
lates APP processing in primary cultured cortical neurons by
analyzing APP C-terminal fragments (CTFs), soluble APP
(sAPP) and A1-40 levels, and cleavage of a reporter APP pro-
tein. We report that synaptic NMDA receptor activity stimulates
nonamyloidogenic-secretase-mediated APP processing and in-
hibits A production and release.
Materials andMethods
Antibodies
Rabbit polyclonal antibody (pAb) CT20 raised against residues 676–695
of human APP (APP695 numbering) has been described previously
(Perkinton et al., 2004); APP C-terminal, phospho-APP (Thr668), and
phospho-ERK1/ERK2 (Thr202/Tyr204) rabbit polyclonal Abs were pur-
chased from Cell Signaling Technology; mouse monoclonal APP Ab
13-M raised against a 21 aa sequence in theN-terminal domain of human
APP, and which is identical in mouse and rat APP, was purchased from
Alpha Diagnostic International; mouse monoclonal APP Ab 22C11 that
recognizes amino acids 66–81 in the N terminus of APP, and MAP2
rabbit polyclonal antibody were purchased from Millipore Bioscience
Research Reagents; PSD-95 monoclonal Ab (mAb) was purchased from
Calbiochem; ERK2 (C-14) rabbit polyclonal antibody was purchased
from Santa Cruz Biotechnology; -tubulin III rabbit pAb and synapto-
physin (clone SVP-38) mouse mAb were purchased from Sigma ; gluta-
mate receptor NMDAR1 (clone 54.1) mAb was purchased from BD Bio-
sciences; synaptophysin 1 rabbit polyclonal Ab was purchased from
Synaptic Systems; AlexaFluor 350, AlexaFluor 488, and AlexaFluor 594
secondary Abs were purchased from Invitrogen; and HRP-conjugated
secondary Abs were purchased from Millipore Bioscience Research Re-
agents. Unless otherwise indicated, primary Abs were used for immuno-
blotting at the following dilutions: APP CT20 (1:20,000), APP
C-terminal and phospho-APP (Thr668) (1:2000), APP 13-M (1:2000),
ERK2 (1:2000), phospho-ERK1/ERK2 (1:2500), synaptophysin 1
(1:2000), and -tubulin III (1:2000).
Compounds
L-Glutamate, NMDA, D-AP5, ()-MK801, CNQX, EGTA, Nifedipine, and
L685,458 were purchased from Sigma; N-[N-(3,5-difluorophenacetyl)-L-
alanyl]-(S)-phenylglycine t-butyl ester (DAPT) and Boc-D-FMK were
purchased from Calbiochem; 4-AP and ()-bicuculline were purchased
from Axxora; TAPI-1 was purchased from Peptides International; Com-
plete Protease Inhibitor Cocktail tablets were purchased from Roche
Applied Science; and the small molecule BACE1 inhibitor, Compound 3
(C3), was kindly provided by Merck Research Laboratories.
CNQX, DAPT, TAPI-1, C3, ()-bicuculline, L685,458, and Boc-D-
FMKweremade up as 1000 concentrated stocks inDMSO (Sigma). All
other compounds were made up as 1000 concentrated stocks in ultra-
pure water.
Plasmids
pRC-CMV vector containing a cDNA encoding for human APP695
fused in-frame at its C terminus via a 5 glycine hinge to the yeast tran-
scription factor Gal4 containing both the DNA-binding and activation
domains (APP695-Gal4) was kindly provided by Prof. Tommaso Russo
(Department of Biochemistry Federico II, University of Naples, Naples,
Italy). pRC-CMV vector containing a cDNA encoding for human
APP695 fused in-frame at its C terminus to the Gal4 DNA-binding do-
main (APP695-Gal4DBD) was created using pRC-CMV vector contain-
ing the cDNA encoding for APP695-Gal4 as a template and introducing
a stop codon immediately after the Gal4 DNA-binding domain using the
QuikChange Site-Directed Mutagenesis kit according to the manufac-
turer’s instructions (Stratagene). pFR-Luciferase reporter vector con-
taining the firefly (Photinus pyralis) luciferase gene under the control of a
synthetic promoter consisting of five tandem repeats of the yeast GAL4
activation sequence upstream of a minimal TATA box, and phRL-
thymidine kinase (TK) vector containing the sea pansy (Renilla renifor-
mis) luciferase gene under the control of the HSV (herpes simplex
virus)-TK promoter, were from Promega. Plasmid containing a cDNA
encoding for human Fe65 has been described previously (Perkinton et
al., 2004). Plasmid containing a cDNA encoding for human APP695
fused in-frame at its C terminus to enhanced green fluorescent protein
(APP–GFP), which was created by cloning of the human APP695 coding
sequence in which the stop codon had been removed, into pEGFP-N1
vector (Clontech) as a SalI fragment, was kindly provided by Prof. Chris
Miller (Medical Research Council Centre for Neurodegeneration Re-
search, Institute of Psychiatry, London, UK).
Primary neuronal culture
Primary cortical neuronal cultures were prepared as described previously
(Perkinton et al., 1999). Briefly, cortices were dissected from embryonic
day 15–16 Swiss mouse embryos (Harlan) and mechanically dissociated
using a fire-polished glass Pasteur pipette in HBSS (Ca2- and Mg2-
free). Neurons were plated into Nunc multiwell tissue culture plates
that had been coated previously with 20 g/ml poly-D-lysine (Sigma)
and were maintained in neurobasal medium without phenol red,
supplemented with B-27, 2 mM glutamine, 100 g/ml streptomycin,
and 60 g/ml penicillin (Invitrogen), at 37°C in a humidified atmo-
sphere of 95% air and 5% CO2. Cultures were used after 9 –14 d in
vitro (DIV) and, under these conditions, were97–99% neuronal, as
judged by -tubulin III staining. Glial elements were2%, as judged
by GFAP staining.
Neuronal transfections
APP-GFP plasmid (1 g) was transfected into primary cortical neurons
cultured on glass coverslips in 12-well plates (2 105 cells per well) at 8
DIV using Lipofectamine 2000 (1l) (Invitrogen) according to theman-
ufacturer’s instructions. Neurons were analyzed 24 h after transfection.
Immunofluorescence and image acquisition
Primary cortical neurons at 14 DIV, cultured on glass coverslips, were
fixed at room temperature in PBS, pH 7.4, containing 4% paraformalde-
hyde for 10min. For labeling of cell surface APP, neuronswere incubated
in blocking buffer (PBS, pH 7.4, containing 5% skimmed milk) for 15
min. For all other immunofluorescence labeling, neuronswere incubated
in blocking permeabilization buffer (PBS, pH 7.4, containing 5%
skimmed milk, 0.1% Triton X-100) for 15 min. Primary Abs: APP CT20
(1:1500 dilution), 22C11 for labeling cell surface APP (1:500 dilution),
MAP2 (1:1000 dilution), NR1 (clone 54.1) (1:150 dilution), PSD-95 (1:
100 dilution), and synaptophysin (1:150 dilution) were applied in Ab
buffer (PBS, pH 7.4, containing 1% skimmed milk) for 2 h, followed by
application of AlexaFluor 350 (1:1000 dilution), AlexaFluor 488 (1:2000
dilution), or AlexaFluor 594 (1:2000 dilution) secondary Abs in Ab
buffer for 1 h. Data were only acquired from healthy nonapoptotic neu-
rons as judged by assessment of nuclear morphology with 4,6-
diamidino-2-phenylindole (DAPI) stain. Incubation of neurons with
secondary Abs in the absence of primary Abs produced a very weak
diffuse staining of cell bodies that did not overlap with the primary
Ab-specific staining (data not shown). Inmultiple label experiments, the
labeling patterns were the same as those seen with single labeling. Mul-
tichannel fluorescence (DAPI–FITC–Texas Red filter set) images were
captured using AxioVision (release 4.6) imaging software and either a
Plan-Apochromat 20 0.75 NA objective or a Plan-Apochromat 63
1.4 NA oil objective fitted to an ApoTome workstation (Axioplan 2 im-
aging microscope with Apotome slider module, motorized focus, and an
AxioCam MRm cooled monochrome digital camera set at 1388 1040
pixel resolution) (Carl Zeiss). Channels were imaged sequentially to
eliminate bleed-through. Z-stack images were captured at 200 nm depth
intervals, Z-series projections were acquired using ImageJ software
(NIH), and multichannel image overlays were obtained using Adobe
Photoshop 7.0 (Adobe Systems).
Detection of APP695 and APP CTFs
To detect APP695 and APP CTFs, primary cortical neurons cultured in
six-well plates (2 106 cells per well) for 9 DIV were treated (as detailed
in the figure legends), washed once with PBS, pH 7.4, and lysed imme-
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diately in 100 l of SDS-PAGE sample buffer (62.5 mM Tris, pH 6.8, 2%
SDS, 5% 2-mercaptoethanol, 10% glycerol, and 0.0025% bromophenol
blue), and then boiled for 5 min. For APP695 detection, samples were
resolved by 8% Tris-glycine SDS-PAGE, and for APP CTFs detection,
samples were resolved by 16.5%Tris-tricine SDS-PAGE (cathode buffer:
0.1 M Tris, 0.1 M tricine, 0.1% SDS; anode buffer: 0.2 M Tris-HCl, pH 8.9).
After gel electrophoresis, proteins were transferred to 0.45 m nitrocel-
lulose (GE Healthcare) for APP695 detection or 0.2 m Immobilon
polyvinylidene difluoride (PVDF)membranes (Millipore) for APPCTFs
detection. Immunoblotting for APP695 was performed using primary
polyclonal APPAbs CT20 (1:20,000 dilution) or phospho-APP (Thr668)
(1:2000 dilution), and HRP-conjugated goat-anti-rabbit IgG secondary
Ab (1:20,000 dilution). Immunoblotting for APP CTFs was performed
using primary polyclonal APP Abs CT20 (1:75,000 dilution), or APP
C-terminal (Cell SignalingTechnology) (1:10,000 dilution), or phospho-
APP (Thr668) (1:15,000 dilution), andHRP-conjugated goat-anti-rabbit
IgG secondary Ab (1:200,000 dilution). APP695 bands were detected
using the ECL system (GE Healthcare), and APP CTFs bands were de-
tected using the ECL Advance system (GE Healthcare), followed by ex-
posure to Hyperfilm ECL according to the manufacturer’s instructions
(GE Healthcare).
Activation of synaptic and extrasynaptic NMDA receptors in
primary cultured cortical neurons
To activate synaptic NMDA receptors (“synaptic protocol”), the con-
ditioned neurobasal medium of primary cultured cortical neurons at
10 DIV was removed, and neurons were exposed to fresh neurobasal
medium containing 1 mM 4-AP and 25 M bicuculline for 15 min.
DMSO or water vehicle was added to wells not receiving treatments.
This protocol has previously been reported to selectively stimulate
synaptic NMDA receptors in large populations of neurons in culture
(Hardingham et al., 2002).
To activate extrasynaptic NMDA receptors (“extrasynaptic proto-
col”), the conditioned neurobasal medium of primary cultured cortical
neurons at 10 DIV was removed, and neurons were exposed to fresh
neurobasal medium containing 1mM 4-AP, 25M bicuculline, and 5M
MK801 for 5 min to activate and block synaptic NMDA receptors. Then,
neurons were washed four times with fresh neurobasal medium to re-
move unbound MK801, followed by addition of neurobasal medium
containing either water vehicle (control) or 50 M NMDA for 15 min.
This protocol has previously been reported to selectively stimulate extra-
synaptic NMDA receptors (Hardingham et al., 2002; Ivanov et al., 2006).
Detection of sAPP
For detection of sAPP in the neuronal culturemedium, primary neurons
cultured in six-well plates (2 106 cells per well) for 9 DIV were treated
as detailed in the legend to Figure 8, followed by removal of the neuronal
culture medium into tubes containing Complete Protease Inhibitor
Cocktail. Samples were then centrifuged at 20,000 g for 15 min at 4°C
to remove cell debris and boiled for 5 min in SDS-PAGE sample buffer.
Samples (15 l) were resolved by 8% SDS-PAGE and transferred to 0.2
m Immobilon PVDF membranes (Millipore). Immunoblotting was
performed using primary mAb APP 13-M (1:15,000 dilution) and HRP-
conjugated goat-anti-mouse IgG secondary Ab (1:50,000 dilution), and
immunoreactive bands were detected using the ECL Plus detection sys-
tem and Hyperfilm ECL according to the manufacturer’s instructions
(GE Healthcare).
Assessment of neurotoxicity: lactate dehydrogenase release
Protocol 1. Primary cortical neurons cultured in 12-well plates (0.5 106
cells per well) for 9 DIV were treated with vehicle (control) or 50 M
NMDA for 15min, 60min, 180min, and 24 h as detailed in the legend to
Figure 8. At the end of each time point, a sample of the neuronal culture
medium was removed, and neurotoxicity was evaluated by measuring
the amount of lactate dehydrogenase (LDH) released by dead and dying
cells using theCytoTox 96 nonradioactive cytotoxicity assay according to
the manufacturer’s instructions (Promega), as described previously
(Molina-Holgado et al., 2008). Absorbance was measured at 490 nm
using aVersaMaxmicroplate reader. BackgroundLDHrelease (neuronal
culture medium alone) was subtracted from the experimental values.
Protocol 2. To assess the effect of acute NMDA or 4-AP/bicuculline
treatments on neuronal viability 24 h later (delayed neurotoxicity), the
conditioned neuronal culture medium from primary cortical neurons at
9 DIV cultured in 12-well plates (0.5 106 cells per well) was removed
and replaced with conditioned medium containing either 50MNMDA
for 5 min, or 1 mM 4-AP and 25 M bicuculline for 15 min. After drug
washout, neurons were returned to the incubator in conditioned neuro-
basal medium for 24 h, followed by removal of samples of themedium to
evaluate LDH release using the CytoTox 96 nonradioactive cytotoxicity
assay according to the manufacturer’s instructions (Promega).
Phase contrast microscopy
Morphological assessment of the effect of NMDA on neuronal viability
was made by phase contrast microscopy. Images were captured with a
Zeiss AxioCamMRm cooled monochrome digital camera set at 1388
1040 pixel resolution and AxioVision (release 4.6) imaging software,
using an Achrostigmat LD 32 0.4 NA Ph1 objective, fitted to a Zeiss
Axiovert S100 microscope (Carl Zeiss).
Mouse A1-40 ELISA
Determination of A1-40 release. To determine the effect of NMDA re-
ceptor activity on A1-40 release from primarymouse neurons, the con-
ditioned medium from primary cortical neurons at 10 DIV cultured in
12-well plates (0.5 106 cells per well) was removed, and neurons were
washed twice with warm (37°C) PBS, pH 7.4, to remove A that had
accumulated with time in culture. Then, 300 l of fresh, warm (37°C)
neurobasal medium without phenol red, supplemented with B-27, con-
taining vehicle or drug treatments as detailed in the legend to Figure 9,
was added to the neurons, which were then returned to the cell culture
incubator for 6 h. After this period, the neurobasal medium (300l) was
transferred to Eppendorf tubes containing Complete Protease Inhibitor
Cocktail and centrifuged at 100,000 g for 30 min at 4°C. Samples (200
l) were then added to amouse/rat A1-40 ELISA plate (code no. 27720;
Immuno-Biological Laboratories) andprocessed for detection ofA1-40
according to the manufacturer’s instructions (Immuno-Biological Lab-
oratories). Mouse A1-40 levels were calculated from a mouse/rat
A1-40 standard curve.
Determination of intracellular A1-40 levels. Neurons used for deter-
mination of A1-40 release (see above) were washed twice with PBS, pH
7.4, and solubilized in 200 l of ice-cold modified RIPA buffer (50 mM
Tris-HCl, pH7.4, 150mMNaCl, 0.5% sodiumdeoxycholate, 0.5%Triton
X-100, 0.1% SDS, 1 mM EGTA, plus Complete Protease Inhibitor Cock-
tail) and left on ice for 1 h. Samples were then centrifuged at 100,000 g
for 30 min at 4°C, and supernatants (100 l) were added to a mouse/rat
A1-40 ELISA plate (code no. 27720; Immuno-Biological Laboratories)
and processed for detection of A1-40 according to the manufacturer’s
instructions (Immuno-Biological Laboratories). Mouse A1-40 levels
were calculated from a mouse/rat A1-40 standard curve.
Dual-Glo luciferase reporter gene activity assay for quantification
of -secretase-mediated cleavage of a human APP695-Gal4 fusion
protein
pFR-Luciferase reporter gene, APP695-Gal4, APP695-Gal4DBD, and
Fe65 plasmids (all 0.5g) were transfected into primary cortical neurons
at 8 DIV cultured in 12-well plates (2  105 cells per well), using Lipo-
fectamine 2000 (1 l/well) (Invitrogen), as detailed in the legend to
Figure 10. All wells were cotransfected with phRL-TK plasmid (0.5 g),
which constitutively expresses moderate levels of Renilla luciferase.
Transfection mixes containing lipid and DNA were prepared in Opti-
MEM I reduced serum medium (Invitrogen) by vortexing for 1 s and
leaving for 25min. Neuronal cultures were removed from the incubator,
and transfectionmixes (150l/well) were added dropwise onto the neu-
ronal culture medium, after which, neuronal cultures were returned to
the incubator. Neurons were treated with various compounds (as de-
tailed in the legend to Figure 10) and processed 24 h after transfection for
quantification of firefly luciferase reporter gene and constitutive Renilla
luciferase expression as described previously (Perkinton et al., 2004).
Briefly, neurons were lysed with Glo Lysis Buffer (40l/well) (Promega),
and theDual-Glo luciferase activity assaywas performed according to the
manufacturer’s instructions (Promega). Luciferase signals were captured
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using a Veritas microplate luminometer
(Turner BioSystems). Firefly luciferase reporter
activity was normalized using the constitutive
Renilla luciferase activity, which helps to differ-
entiate between specific and nonspecific cellu-
lar responses and also controls for transfection
efficiencies across experiments.
Quantification and statistics
Immunoblot Hyperfilm ECL bands were quan-
tified by scanning intoNIH ImageJ software at a
resolution of 1200 dots per inch using an Epson
Perfection V700 Photo flatbed scanner fitted
with a Transparency Unit, and the mean
background-corrected optical density (OD) of
each band was interpolated from an OD cali-
4
Figure 1. APP is trafficked to both presynaptic and
postsynaptic compartments in primary cortical neurons.
A–B**, Double immunofluorescence staining of primary cul-
tured cortical neurons at 14 DIV. Neuronswere fixed and dou-
ble immunostained for APP andMAP2 (A–A**), and APP and
the presynaptic marker synaptophysin (SYN) (B–B**). A**,
Image overlay showing localization of cell surface APP to
MAP2-positive dendrites. Cell surface APP was labeled with
mouse monoclonal APP Ab 22C11 that recognizes the N ter-
minus of APP, followed by cell permeabilization and labeling
of MAP2 with a MAP2 rabbit pAb. Bottom, Higher-
magnification image of area indicated by white arrows in top
panel. B**, Image overlay showing a pool of cell surface APP
is apposed to SYN-immunoreactive puncta, suggesting that
APP is trafficked to synapses in primary cortical neurons. Cell
surface APP was labeled with mouse monoclonal APP Ab
22C11 that recognizes the N terminus of APP, followed by cell
permeabilization and labeling of SYN with a SYN rabbit pAb.
Examples of APP-positive puncta adjacent to SYN are shown
in the bottom panel (white arrows), which is a higher-
magnification image of the area indicated by thewhite box in
the top panel. C–C** and D–D**, A plasmid encoding for
APP-GFP (1g)was transfected intoprimary cortical neurons
at 8 DIV using Lipofectamine 2000 (1 l). Immunofluores-
cence labeling for SYNwas performed 24 h after transfection.
Only neurons expressing low to moderate levels of APP-GFP
were analyzed. Images were captured from areas in which
there was only a single neuron expressing APP-GFP (when
using a 20 objective). C–C**, Image series showing colo-
calization of axonal APP-GFPwith SYN, suggesting that a pool
of APP is trafficked to presynaptic nerve terminals in primary
cortical neurons. C, Top, Low-magnification image of a neu-
ron expressing APP-GFP; axonal and dendritic arborizations
are indicated. C**, Image overlay showing colocalization of
axonal APP-GFPwith SYN. Bottom, Higher-magnification im-
age of the axon region indicated by two white arrows in the
top panel. Discrete APP-GFP and SYN-positive puncta are vis-
ible; colocalization of APP-GFP with SYN is indicated by nu-
merous white arrows in bottom panel. D–D**, Image series
showing dendritic APP-GFP apposed to SYN-immunoreactive
puncta, suggesting that a pool of APP-GFP is trafficked to syn-
apses in primary cortical neurons. D**, Image overlay show-
ing a pool of dendritic APP-GFP is apposed to SYN-
immunoreactive puncta. Neurons were also immunostained
for MAP2 to reveal dendrites (blue). Examples of APP-GFP
puncta adjacent to SYN are shown in panels 1–6, which are
higher-magnification images of the dendritic regions indi-
cated by numbered arrows in D**. Scale bars: A, B, 20 m
(top), 1m (bottom); C, 50m (top), 5m (bottom);D, 25
m (top), 1m (panels 1–6 ).
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bration curve created using anOD step tablet. OnlyHyperfilm exposures
that gave band OD values that were within the linear range of the OD
calibration curve were used for statistical analysis.
Mean data  SEM were graphed using GraphPad Prism software.
Immunoblot, A1-40 ELISA, and Dual-Glo luciferase activity assay data
were analyzed by one-way ANOVA with Bonferroni’s post test, or by
two-tailed Student’s t tests, using GraphPad Instat software. Differences
between experimental treatments were considered to be statistically sig-
nificant when p 0.05.
Results
APP is trafficked to both presynaptic and postsynaptic
compartments and is expressed in glutamatergic neurons
It has recently been reported that under steady-state conditions
APP is sorted equally to the axonal and somatodendritic com-
partment in primary neurons (Back et al., 2007). We examined
the distribution pattern of endogenous APP and the trafficking of
APP-GFP in primary cultured cortical neurons. We performed
double immunofluorescence labeling for cell surface APP and the
dendritic markerMAP2. Using APP Ab 22C11, which recognizes
amino acids 66–81 in the N-terminal extracellular domain of
APP, we observed a discrete punctate pattern of surface APP
staining along the length of MAP2-positive dendrites (Fig. 1A–
A**), suggesting that APP is trafficked to the dendrites of primary
cultured cortical neurons. However, on the basis of these data, we
could not rule out the possibility that the APP-immunopositive
puncta we observed along the length of dendrites were actually
presynaptic in origin. To address this, we performed double im-
munofluorescence labeling for APP and the presynaptic marker
synaptophysin.We found little evidence of APP colocalizing with
synaptophysin in dendritic regions but instead observed numer-
ous APP-positive puncta that were apposed to synaptophysin-
immunopositive puncta (Fig. 1B–B**), which strongly suggests
that there is a pool of APP that is trafficked to postsynaptic sites.
In addition, analysis of cultured cortical neurons expressing
APP-GFP revealed that APP-GFP is trafficked to both axons and
dendrites (Fig. 1C). Axonal APP-GFP strongly colocalized with
synaptophysin (Fig. 1C–C**, bottom panel), suggesting that APP
is trafficked to presynaptic nerve terminals or boutons. In sup-
port of this finding, it has previously been demonstrated that a
large proportion of endogenous axonal APP colocalizes with syn-
aptophysin (Sabo et al., 2003). However, of particular relevance
to our study, we observed that at numerous sites along dendrites,
APP-GFP appeared to be apposed to synaptophysin-
immunoreactive puncta (Fig. 1D–D**, boxes 1–6), which corre-
lates well with the labeling patterns of endogenous APP and syn-
aptophysin in dendritic regions (Fig. 1B–B**).
Considering that our primary aim was to study whether glu-
tamatergic neuronal activity regulates APP processing, we next
assessed whether APP was expressed in glutamatergic neurons.
Z-series projections of primary cortical neurons double labeled
for APP and the NR1 subunit of the NMDA receptor revealed
that APP and NR1 partially overlap in intracellular compart-
ments (Fig. 2A–A**) and somatodendritic compartments (Fig.
2B–B**). Partial overlap of APP and NR1 immunofluorescence
was also observed in neuritic processes (Fig. 2C–C**). In addi-
tion, double immunofluorescence labeling for APP and the
NMDA receptor scaffolding protein PSD-95 revealed overlap of
APP and PSD-95 in intracellular compartments (Fig. 2D–D**)
and in neuritic processes (Fig. 2E–E**).
Altogether, our data suggest that a pool of APP is expressed
postsynaptically in which it partially overlaps with NR1 and
PSD-95. In support of our findings, it has previously been
demonstrated using immunoelectron microscopy that a mi-
nor proportion of APP is localized to the postsynaptic density
region of asymmetrical synapses in rat cortical neurons
(Shigematsu et al., 1992).
APP695 is the major APP isoform in primary cultured
cortical neurons
APP is a type 1 transmembrane protein, and there are threemajor
isoforms containing 695, 751, or 770 aa residues, termedAPP695,
APP751, and APP770, respectively (Wilquet and De Strooper,
2004). They are generated by alternative splicing of mRNA de-
rived from a single gene. Under normal physiological conditions,
APP695 is the major isoform expressed in neurons, and expres-
sion of APP751 and APP770 is barely detectable (Buxbaum et al.,
1998a). APPundergoes extensive posttranslationalmodifications
including N- and O-linked glycosylation, phosphorylation, and
tyrosine sulfation (Weidemann et al., 1989; Buxbaum et al., 1990;
Oltersdorf et al., 1990). We prepared cell lysates from primary
cultured mouse cortical neurons and performed SDS-PAGE and
immunoblotting with APP Ab CT20 that is specific for the
C-terminal residues 676–695 of APP695, and which will detect
all full-length unprocessed cellular APP isoforms. We observed
three discrete polypeptide bands running just above the 98 kDa
molecular weight marker. Based on previous findings (Buxbaum
et al., 1998a), we assigned the lowest andmajor band asN-linked
immatureAPP695, and the two slowermigrating bands asN- and
O-linked mature forms of APP695 (Fig. 3A). We did not detect
any other higher molecular weight bands with APP Ab CT20;
thus, the major isoform of APP in primary mouse cortical neu-
ronal cultures appears to be APP695.
Characterization of APP CTFs in mouse primary cultured
cortical neurons
In neurons, cleavage of APP by -secretase results in the forma-
tion of a membrane-embedded CTF 83 aa in length, termed C83,
and cleavage of APP by -secretase results in the formation of
membrane-embedded CTFs 89 or 99 aa in length, termed C89
and C99, respectively (Buxbaum et al., 1998a; Kimberly et al.,
2005). These CTFs, which range in size from8 to 14 kDa, can be
phosphorylated on specific amino acid residues including
Thr668 and Tyr682 (APP695 numbering) (Suzuki et al., 1994;
Standen et al., 2001; Zambrano et al., 2001; Tarr et al., 2002),
however, the functional consequence of CTF phosphorylation
has not been fully resolved. After cleavage by -secretase or
-secretase, it is thought that CTFs undergo complex intramem-
braneous processing by a multiprotein -secretase complex that
minimally includes presenilin, PEN-2, APH-1, and nicastrin,
which generates a cytosolic APP intracellular domain (AICD)
fragment (Wolfe, 2006).
We reasoned that APP CTFs would provide a sensitive read-
out to study secretase-dependent regulation of APP processing
since they are generated in cells directly after cleavage of APP by
-secretase and-secretase. First, we characterized the pattern of
APP CTFs in primary mouse cortical neurons. We analyzed APP
CTFs using 16.5%Tris-tricine SDS-PAGE, followed by immuno-
blotting using C-terminally directed APP pAbs that should rec-
ognize total (phosphorylated and nonphosphorylated) CTF lev-
els: (1) an in-house APP Ab, APP CT20, raised against residues
676–695 of APP695; and (2) a commercially available APP pAb
raised against residues surrounding threonine 668 (APPCT).We
observed four discrete bands in the 7–16 kDa molecular weight
marker range (Fig. 3B, asterisks) that appeared to run at the cor-
rect molecular weight of APP CTFs, as judged by running our
cortical neuron samples alongside lysate samples prepared from
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HeLa cells overexpressing APP695, or APP695 and BACE1 (Fig.
3B). Both APP Abs revealed identical band patterns, strongly
suggesting that these bands represent APP CTFs. Furthermore, it
is known that APPCTFs exist as amixture of phosphorylated and
nonphosphorylated forms, and we exam-
ined the pattern of phosphorylated CTFs
in primary cortical neurons by performing
immunoblotting using a C-terminally di-
rected APP pAb specific for the phosphor-
ylated Thr668 residue of APP (P-
T668APP), and which will detect
phosphorylated APP CTFs. We observed
three discrete bands in the 7–16 kDa
marker range (Fig. 3B, asterisks).
Regarding our data with APPAbCT20,
and based on previous observations (Bux-
baum et al., 1998a; Kimberly et al., 2005),
we concluded that the faint lowest molec-
ular weight band is nonphosphorylated
C83 generated from -secretase activity;
the next and noticeably stronger band is a
mixture of phospho-C83 and -secretase-
generated nonphosphorylated C89; the
third band is phospho-C89; and the faint
highest molecular weight band represents
either nonphosphorylated or phosphory-
lated C99 generated from -secretase
cleavage. With respect to our data ob-
tained using the APP polyclonal antibody
specific for the phosphorylated Thr668
residue of APP (P-T668APP), we con-
cluded that the lowest molecular weight
phospho-CTF band was phospho-C83;
the middle band was phospho-C89; and
the faint highest molecular weight band
was phospho-C99.
We also characterized the nature of
APP CTFs in primary mouse cortical neu-
rons using a range of APP secretase inhib-
itors. We found that treatment of cortical
neuronal cultures with the nontransition
state -secretase inhibitor, DAPT, mas-
sively and specifically increased the immu-
noreactive signal detected between 7 and
16 kDa compared with the control signal
(Fig. 3C, DAPT vs control). It has previously
been reported that inhibition of -secretase
with DAPT leads to accumulation of
-secretase and -secretase-generated CTFs
(Dovey et al., 2001; Sastre et al., 2001), and
thus, our data with DAPT also confirmed
that the APP-immunoreactive bands we de-
tected between 7 and 16 kDa were bona fide
-CTF and -CTF. However, to strengthen
our conclusions regarding the pattern of
CTFs in primary cortical neurons, we per-
formed experiments with the small-
molecule cell-permeable -secretase
BACE1 inhibitor, Merck C3 (Stachel et al.,
2004) and the broad-spectrum cell-
permeable -secretase (ADAM) inhibitor,
TAPI-1 (Hooper et al., 1997; Slack et al.,
2001), and then compared the pattern of
CTFs to the control pattern.We found that treatment of neurons
with C3 markedly altered the total CTF and phospho-CTF pat-
tern (Fig. 3C). It is noticeable in Fig. 3C that when comparedwith
the control sample, the upper two total CTF bands are largely
Figure2. APPisexpressedinprimarycorticalglutamatergicneurons.A–E**,Doubleimmunofluorescencestainingofprimarycultured
corticalneuronsat14DIV.Neuronswerefixedanddouble immunostainedforAPPandNR1(A–A**,B–B**,C–C**),andAPPandPSD-95
(D–D**,E–E**).A**,Mid Z-stack imageoverlay showingpartial overlapofAPPwithNR1 in the intracellular compartment, as indicated
by white arrows. B**, Top Z-stack image overlay showing partial overlap of APP with NR1 in the somatodendritic compartment, as
indicatedbywhitearrows.C**, ImageoverlayshowingpartialoverlapofAPPwithNR1inneuriticprocesses.Middle,Higher-magnification
imageofareaindicatedbythreewhitearrows(toprightoftoppanel).Bottom,Higher-magnificationimageofareaindicatedbytwowhite
arrows (bottom left of top panel). D**, Image overlay showing partial overlap of APP with PSD-95, as indicated by white arrows. E**,
ImageoverlayshowingpartialoverlapofAPPwithPSD-95inneuriticprocesses,as indicatedbywhitearrowheads.Scalebars:A,B,10m;
C, 20m(top), 1m(bottom);D, 10m; E, 5m.
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absent in samples prepared from neurons treated with C3, and
the upper two phospho-CTF bands were similarly absent in C3-
treated neurons. Additionally, when comparedwith control sam-
ples, C3 treatment increased the levels of the two lowest molecu-
larweight total CTFbands and the lowest phospho-CTFband.C3
is reported to be a highly specific small-molecule BACE1 inhibi-
tor (Stachel et al., 2004); thus, our C3 data strongly suggest that
the upper two total CTF and phospho-CTF bands are generated
from BACE1 cleavage of APP and represent C89 and C99 CTFs,
and thus, it is likely that the lowest molecular weight total CTF
and phospho-CTF band is C83 generated from -secretase activ-
ity. As a point of interest, our observed increase in C83 levels in
the presence of C3 also suggests that in neurons, blocking
BACE1-mediated cleavage of APP leads to increased -secretase
cleavage of APP. Alternatively, treatment of neurons with the
-secretase inhibitor, TAPI-1, also markedly altered the total
CTF and phospho-CTF pattern (Fig. 3C). It can be seen from
Figure 3C, and especially evident in the phospho-CTF immuno-
blot, that when compared with the control sample, TAPI-1 treat-
ment markedly decreased the levels of the lower CTF band, and
increased the levels of the upper two CTF bands. These results
lend further support to our conclusion that the lowest CTF band
is -secretase-generated C83, and the upper two CTF bands are
-secretase-generated C89 and C99. Furthermore, our observed
increase in C89 and C99 levels in the presence of TAP1–1 further
confirms that blocking one secretase processing pathway appears
to redirect APP processing down the alternative secretase-
processing pathway in primary cultured cortical neurons.
Glutamate increases-CTF (C83) levels in primary cultured
cortical neurons
Having demonstrated that a pool of APP is localized to the
postsynaptic region of glutamatergic cortical neurons, and after
establishing the pattern of APP CTFs in primary mouse cortical
neuronal cultures, we performed experiments to determine
whether application of the major excitatory neurotransmitter
L-glutamate to the cortical cultures altered the pattern of APP
CTFs.We treated cortical neurons with glutamate (20M) for 15
min and prepared samples for detection of APP CTFs. We found
that glutamate treatment caused a 2.5-fold increase in
-secretase-generated C83 levels compared with control levels
(Fig. 4A,D) and also led to a marked increase in phospho-C83
levels (Fig. 4A). Our observed difference in C83 levels between
control and glutamate-treated neurons was not the result of dif-
ferences in the total levels of protein loaded onto gels, because the
total levels of full-length APP695 in control and glutamate-
treated cultures were the same (Fig. 4A). After analysis of
-secretase-generated C89 and phosphoC89 levels, we failed to
find any difference between control and glutamate-treated cul-
tures (Fig. 4A,D), suggesting that glutamate treatment was only
altering the levels of C83. To assess whether our observed
glutamate-evoked increase inC83 levelswas due to stimulation of
NMDA-type glutamate receptors, we treated cortical neurons
with glutamate in the absence or presence of the competitive and
selective NMDA receptor antagonist D-AP5. We found that
whereas D-AP5 had no noticeable effect on control CTF levels, it
completely blocked the glutamate-evoked increase in C83 levels
(Fig. 4B), strongly suggesting that our observed glutamate effects
were NMDA receptor driven.We also found that MK801, a non-
competitive open-channel blocker of the NMDA receptor, pre-
vented the glutamate-mediated increase inC83 levels (Fig. 4C,D),
lending additional support to our conclusion that glutamate was
having its effects on APP CTF levels through stimulation of
NMDA-type glutamate receptors.
When activated, a primary function of NMDA receptors is to
allow the influx of extracellular Na and Ca2 into dendritic
spines (Malinow et al., 1994). Essentially, the NMDA receptor is
an ionotropic signaling receptor, and it is the influx of Ca2
through NMDA receptors that is responsible for triggering nu-
merous cell signaling events involved in synaptic plasticity, and
learning and memory processes (Bliss and Collingridge, 1993).
We assessed the role of extracellular Ca2 in our glutamate-
Figure 3. Characterization of APP and APP CTFs in primary cultured cortical neurons. A,
Lysate prepared fromprimary cultured cortical neurons at 10 DIVwas immunoblottedwith APP
Ab CT20. Bands representing N-linked (immature) and NO-linked (mature) APP695 are indi-
cated.B, Cell extracts prepared fromnontransfectedHeLa cells (NT), HeLa cells transfectedwith
a plasmid encoding for APP695 (APP695), or HeLa cells cotransfected with plasmids encod-
ing for APP695 andBACE1 (APP695BACE1),were resolved by 16.5%Tris-tricine SDS-PAGE
and immunoblotted with APP Ab CT20. Cell extracts prepared from primary cultured cortical
neurons at 10 DIV were resolved by 16.5% Tris-tricine SDS-PAGE and immunoblotted with APP
Ab CT20, a commercial APP C-terminal Ab (APP CT), or phospho-APP (thr668) Ab (P-T668APP).
APP CTF bands are indicated by asterisks. C, Primary cultured cortical neurons at 10 DIV were
treated with DMSO (control), 2M DAPT, 10M BACE1 inhibitor C3, or 50M TAPI-1 for 3 h
followed by immunoblotting of cell extracts with APP Ab CT20 to detect total (unphosphory-
lated and phosphorylated) APP CTFs (top) or phospho-APP (Thr668) Ab (P-T668APP) to detect
phospho-CTFs (bottom).
4448 • J. Neurosci., April 8, 2009 • 29(14):4442–1460 Hoey et al. • NMDA Receptors Regulate APP Processing
evoked increase in C83 levels in cortical neurons. We found that
treatment of neurons with glutamate in the absence of extracel-
lular free Ca2, which was chelated by addition of EGTA to the
neurobasal medium, failed to elicit an increase in C83 levels
above control levels (Fig. 4C,D), suggesting that extracellular
Ca2 is required for glutamate-evokedmodulation of C83 levels.
Treatment of neurons with EGTA alone did not alter basal (con-
trol) APP CTF levels (Fig. 4C,D). Furthermore, none of the drug
treatments altered the levels of full-length APP695 (Fig. 4A–C).
NMDA receptor activity increases-CTF (C83) levels in
primary cultured cortical neurons
We confirmed that glutamate was acting at NMDA receptors to
modulate APP C83 levels by directly stimulating NMDA recep-
tors using the specific synthetic agonist NMDA. Treatment of
neurons with NMDA led to an increase in C83 levels similar to
that seen with glutamate, and we determined the pharmacologi-
cal concentration range over whichNMDAwas exerting its effect
on C83 levels to be between 10 and 100 M (Fig. 5A), which is
typical for activation of native NMDA receptors in vitro (Perkin-
ton et al., 2002).We next determined the time course of increased
C83 levels in response to 50 M NMDA treatment and observed
increased C83 levels as early as 5 min after application of NMDA
(Fig. 5B). Treatment of neurons with NMDA for 5 min did not
induce neurotoxicity, whichwas assessed 24 h later using an LDH
release assay [absorbance units (490 nm): control, 0.75 0.016;
50 MNMDA, 0.77 0.01; n 8]. LDH release occurs after cell
plasma membrane damage or rupture and is a widely used
marker of cytotoxicity.
Similar to glutamate, NMDA treatment evoked a 2-fold to
2.5-fold increase in C83 levels, and this effect was blocked by the
NMDA receptor antagonists MK801 (Fig. 5C,F) and D-AP5 (Fig.
5D), strongly suggesting that NMDA receptor channel activity
was mediating the modulatory effect on C83 CTF levels. Our
observed difference in C83 levels between control and NMDA-
treated neurons was not the result of differences in the total levels
of protein loaded onto gels, because the total levels of full-length
APP695 in control and NMDA-treated cultures were the same
(Fig. 5A–E). NMDA treatment also increased the levels of
phospho-C83 (Fig. 5C). However, C89 levels were not altered by
treatment of cortical neurons with NMDA for 15 min (Fig.
5A,F). The NMDA-evoked increase in C83 levels was dependent
on extracellular Ca2, because chelation of extracellular free
Ca2 by addition of EGTA to the neurobasal medium blocked
the NMDA-evoked increase in C83 levels (Fig. 5E,F).
Our results with EGTA strongly indicated that Ca2 influx
through NMDA receptors was responsible for modulating C83
CTF levels. However, to rule out the possibility that NMDA re-
Figure 4. Glutamate increases-CTF (C83) levels in primary cultured cortical neurons. A, Primary cultured cortical neurons at 10 DIV were treated with vehicle (control) or 20M glutamate for
15min followed by immunoblotting of neuronal lysateswith APPAbs CT20 or phospho-APP (thr668) (P-T668APP).B, Primary cultured cortical neurons at 10DIVwere treatedwith vehicle (control),
100M D-AP5, 20M glutamate, or 20M glutamate in the presence of 100M D-AP5 (Glut.D-AP5) for 15 min followed by immunoblotting of neuronal lysates with APP Ab CT20. C, Primary
cultured cortical neurons at 10 DIV were treated with vehicle (control), 2M MK801, 2 mM EGTA, 20M glutamate, 20M glutamate in the presence of 2M MK801 (Glut.MK801), or 20M
glutamate in the presence of 2mM EGTA (Glut.EGTA) for 15min followed by immunoblotting of neuronal lysateswith APP Ab CT20.D, C83 levels in cortical neurons treatedwith vehicle (control),
MK801, EGTA,glutamate, glutamate in thepresenceofMK801 (Glut.MK801), andglutamate in thepresenceof EGTA (Glut.EGTA), andC89 levels in cortical neurons treatedwithvehicle (control)
or glutamate, were analyzed by ECL protein band densitometry using calibrated ImageJ software. Each column is the mean SEM of six independent experiments (n 6; ***p 0.001, control
vs glutamate, one-way ANOVA with Bonferroni post test).
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Figure 5. NMDA receptor activity increases-CTF (C83) levels in primary cultured cortical neurons. A, Primary cultured cortical neurons at 10 DIV were treated with vehicle (control) or 1, 3, 10,
30, and100MNMDA for 15min followedby immunoblottingofneuronal lysateswithAPPAbCT20.B, Primary cultured cortical neuronsat 10DIVwere treatedwithvehicle (control) or 50MNMDA
for 5, 10, 20, 40, and 60min followedby immunoblotting of neuronal lysateswithAPP antibody CT20. C, Primary cultured cortical neurons at 10DIVwere treatedwith vehicle (control), 2MMK801,
50 M NMDA, or 50 M NMDA in the presence of 2 M MK801 (NMDAMK801) for 15 min followed by immunoblotting of neuronal lysates with APP Abs CT20 or phospho-APP (thr668)
(P-T668APP).D, Primary cultured cortical neurons at 10 DIVwere treatedwith vehicle (control), 100M D-AP5, 50MNMDA, or 50MNMDA in the presence of 100M D-AP5 (NMDAD-AP5) for
15 min followed by immunoblotting of neuronal lysates with APP Ab CT20. E, Primary cultured cortical neurons at 10 DIV were treated with vehicle (control), 2 mM EGTA, 50M NMDA, or 50M
NMDA in the presence of 2 mM EGTA (NMDAEGTA) for 15 min followed by immunoblotting of neuronal lysates with APP Ab CT20. F, C83 levels in cortical neurons treated with vehicle (control),
MK801, EGTA, NMDA, NMDA in the presence of MK801 (NMDAMK801), and NMDA in the presence of EGTA (NMDAEGTA), and C89 levels in cortical neurons treated with vehicle (control) or
NMDA, were analyzed by ECL protein band densitometry using calibrated ImageJ software. Each column is themean SEM of six independent experiments (n 6; **p 0.01, control vs NMDA,
one-way ANOVA with Bonferroni post test). G, Primary cultured cortical neurons at 10 DIV were treated with vehicle (control), 50M CNQX, 10M nifedipine, 50M NMDA, 50M NMDA in the
presence of 50M CNQX (NMDACNQX), or 50M NMDA in the presence of 10M nifedipine (NMDANifedipine) for 15min followed by immunoblotting of neuronal lysates with APP Ab CT20.
H, Primary cultured cortical neurons at 10 DIV or 14 DIV were treated with vehicle (Con) or 50M NMDA for 15 min followed by immunoblotting of neuronal lysates with APP Ab CT20.
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ceptor activation might be increasing APP C83 levels via second-
ary Ca2 influx through AMPA-type glutamate receptors,
kainate-type glutamate receptors, or L-type voltage-sensitive
Ca2 channels, we performed experiments with NMDA in the
absence or presence of the selective AMPA/kainate receptor an-
tagonist CNQX, or the L-type voltage-sensitive Ca2 channel
blocker nifedipine.We found that theNMDA-evoked increase in
C83 levels was not diminished by blocking AMPA/kainate gluta-
mate receptors or L-type voltage-sensitive Ca2 channels (Fig.
5G), strongly suggesting that the effect of NMDA on C83 levels
was due to the influx of Ca2 through NMDA receptors.
It has previously been reported that the levels of phosphory-
lated APPCTFs in primary cortical neurons increase with time in
culture (Kimberly et al., 2005), and in agreement with this, we
noticed that there was an increase in the basal levels of phospho-
C83, phospho-C89, and phospho-C99 in 14DIV cortical cultures
compared with 9–10 DIV cultures (Fig. 5H, control). However,
despite this altered basal CTF pattern at 14 DIV, we found that
treatment of cortical neurons with 50 MNMDA for 15 min still
increased the levels of C83 CTF compared with control levels
(Fig. 5H), which indicates that NMDA receptor modulation of
APP CTF levels is not restricted to a single time point in culture.
Finally, none of the drug treatments altered the levels of full-
length APP695 (Fig. 5A–H).
In conclusion, our experimental results with glutamate and
NMDA suggest that over a short timescale of minutes, NMDA
receptor activity selectively enhances -secretase-mediated APP
processing and consequently increases C83 levels.
The-secretase inhibitor TAPI-1 blocks the NMDA-receptor-
mediated increase in C83 levels
C83CTFs are formed from cleavage of APP by-secretase, and in
neurons, the disintegrin metalloproteases ADAM10 and/or
ADAM17 are strongly believed to be the -secretases that medi-
ate nonamyloidogenic constitutive and regulated APP cleavage
(Buxbaum et al., 1998b; Lammich et al., 1999). To test the in-
volvement of ADAM metalloprotease activity in our observed
NMDA-receptor-evoked increase in C83 levels, we conducted
experiments with the widely used broad-spectrumADAM inhib-
itor TAPI-1, which has previously been reported to block consti-
tutive and muscarinic-receptor-stimulated sAPP release in
HEK 293 cells expressing M3 muscarinic receptors (Slack et al.,
2001). Furthermore, our results showing that TAPI-1 blocks
-CTF and phospho--CTF (C83) production in cortical neu-
rons (Fig. 3C) confirmed that TAPI-1 inhibits -secretase-
mediated APP cleavage. We found that pretreatment of cortical
neuronal cultures with TAPI-1 blocked the NMDA-receptor-
mediated increase in C83 levels (Fig. 6A,B). Contrastingly, treat-
ment of cortical cultures with the small molecule BACE1 inhibi-
tor, C3, did not significantly alter the NMDA-evoked increase in
C83 levels (Fig. 6A,B). These results indicate that our observed
NMDA-receptor-evoked increase in C83 levels is dependent on
-secretase (ADAM) activity. Treatment of cortical neurons with
secretase inhibitors did not alter the levels of full-length APP695
over the 15 min time course of the experiment (Fig. 6A).
Synaptic NMDA receptor activity increases-CTF (C83)
levels in primary cultured cortical neurons
Application of NMDA agonist directly into the neurobasal me-
dium (bath application) results in the simultaneous activation of
the total pool ofNMDA receptors (synaptic and extrasynaptic) in
primary cultured cortical neurons. Activation of synapticNMDA
receptors has been implicated in physiological processes such as
long-term potentiation induction, cAMP response element
(CRE)-binding protein (CREB) activation, and synaptic plastic-
ity, whereas extrasynaptic NMDA receptor activity is thought to
occur as a result of pathophysiological processes (Hardingham
and Bading, 2003). Our data with bath application of NMDA and
glutamate does not discriminate between these two pools of
NMDA receptors. To determine whether our observed NMDA-
receptor-mediated modulation of APP processing was due to ac-
tivation of synaptic or extrasynaptic NMDA receptors, we per-
formed a series of experiments to activate synaptic and
extrasynaptic NMDA receptors separately. Activation of synaptic
NMDA receptors can be achieved after bath application of the
K channel blocker 4-AP and the GABAA receptor blocker bicu-
culline, which together increase glutamate-driven activity of the
neuronal network in the cortical cultures. This pharmacologi-
cally induced network disinhibition has previously been reported
to selectively stimulate synaptic NMDA receptors in large popu-
lations of neurons in culture (Hardingham et al., 2002). We con-
firmed that 4-AP/bicuculline treatment increases synaptic neu-
ronal activity by measuring ERK activity, which has previously
been shown to be increased during bicuculline treatment in pri-
Figure 6. The-secretase inhibitor TAPI-1 blocks the NMDA-receptor-mediated increase in
C83 levels. A, Primary cortical neurons at 10 DIV were treated with vehicle (control), 10 M
BACE1 inhibitor C3, 50M TAPI-1, 50M NMDA, 50M NMDA in the presence of 10M C3
(NMDAC3), or 50M NMDA in the presence of 50M TAPI-1 (NMDATAPI-1) for 15 min
followed by immunoblotting of neuronal lysates with APP antibody CT20. Two immunoblots
generated from independent experiments are shown. B, C83 levels were analyzed by ECL pro-
tein band densitometry using calibrated ImageJ software. Each column is the mean SEM
valueof four independent experiments (n4; **p0.01, control vsNMDA,*p0.05,NMDA
vs NMDATAPI-1, one-way ANOVA with Bonferroni post test).
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mary cultured hippocampal neurons
(Hardingham et al., 2001; Ivanov et al.,
2006). To measure ERK activation, we co-
applied 4-AP and bicuculline for 15 min
and then performed immunoblotting of
cortical lysates with an anti-ACTIVE ERK
Ab that detects ERKwhen it is dually phos-
phorylated onThr202 andTyr204 residues
of ERK1 and on Thr183 and Tyr185 resi-
dues of ERK2. We have previously re-
ported that phosphorylation on these res-
idues positively correlates with ERK
activation (Perkinton et al., 1999, 2002). In
line with previous reports, we found that
increasing synaptic activity in the neuro-
nal cultures with 4-AP and bicuculline led
to robust ERK phosphorylation compared
with control levels (Fig. 7A, top panel).
Our observed difference in phospho-
ERK1 and phospho-ERK2 levels between
control and 4-AP/bicuculline-treated neu-
rons was not due to differences in the total
levels of protein loaded onto gels, because
the total levels of ERK1 and ERK2 in con-
trol and 4-AP/bicuculline-treated cultures
were the same (Fig. 7A, bottom panel).
Furthermore, similar to previous reports
(Hardingham et al., 2002), treatment of
cortical neurons with 4-AP/bicuculline for
15 min did not induce any neurotoxicity,
which was assessed 24 h later using an
LDH release assay (data not shown).
We then analyzed the same samples for
APP CTF levels and detected a robust in-
crease in -secretase-generated C83 in
4-AP/bicuculline-treated neuronal cul-
tures compared with control vehicle-
treated cultures (Fig. 7B). These data sug-
gest that increasing synaptic activity
stimulates -secretase-mediated APP
cleavage. Our observed difference in C83
levels between control and 4-AP/
bicuculline-treated neurons was not due
to differences in the total levels of protein
loaded onto gels, because the total levels of
full-length APP695 in control and 4-AP/
bicuculline-treated cultures were the same
(Fig. 7B).
Having established that 4-AP/bicucul-
line treatment increases -CTF (C83) lev-
els in cultured cortical neurons, we inves-
tigated the involvement of synaptic
NMDA receptors by performing 4-AP/
bicuculline experiments in the absence or
presence of the NMDA receptor blocker
MK801. Interestingly, our observed 4-AP/
bicuculline-evoked increase in C83 levels
was prevented by the presence of MK801
in the stimulation solution [Fig. 7C (synaptic protocol),D], sug-
gesting that synaptic NMDA receptor activity is coupled to in-
creased -secretase-mediated APP processing. Additional analy-
sis of these same cortical lysates revealed that 4-AP/bicuculline
treatment did not alter the levels of full-length APP695 over the
15 min time course of the experiment (Fig. 7C, second panel),
and also that 4-AP/bicuculline treatment stimulated ERK phos-
phorylation in a strictly MK801-sensitive manner (Fig. 7C, third
panel, synaptic protocol), confirming that synaptic NMDA re-
ceptors were being activated during the 4-AP/bicuculline treat-
Figure7. SynapticNMDA receptor activity increases C83 levels inprimary cultured cortical neurons.A, Primary cultured cortical
neurons at 10 DIV were treated with vehicle (control) or 1 mM 4-AP and 25 M bicuculline (4-AP/Bic) for 15 min followed by
immunoblotting of neuronal lysates with phospho-ERK1/ERK2 (pERK1/pERK2) and ERK1/ERK2 Abs. B, Primary cultured cortical
neurons at 10 DIV were treated with vehicle (control) or 1 mM 4-AP and 25 M bicuculline (4-AP/Bic) for 15 min followed by
immunoblotting of neuronal lysates with APP antibody CT20. C, Extrasynaptic NMDA receptor activation protocol: primary cul-
tured cortical neurons at 10 DIVwere treatedwith 1mM 4-AP, 25M bicuculline and 5MMK801 for 5min to activate and block
synapticNMDA receptors, followedbywashout of unboundMK801andbath applicationof vehicle (control) or 50MNMDA for 15
min; synaptic NMDA receptor activation protocol: primary cultured cortical neurons were treated with 2M MK801, 1 mM 4-AP
and 25 M bicuculline (4-AP/Bic), or 1 mM 4-aminopyridine and 25 M bicuculline in the presence of 2 M MK801 (4-AP/
BicMK801) for 15min. Neuronal lysates were prepared and immunoblottedwith APP Ab CT20 to detect APP CTFs and APP695,
and also with phospho-ERK1/ERK2 (pERK1/pERK2) and ERK1/ERK2 antibodies. D, C83 levels in cortical neurons treated with
vehicle (control), MK801, 4-AP/Bic, and 4-AP/Bic in the presence of MK801 (4-AP/BicMK801) were analyzed by ECL protein band
densitometry using calibrated ImageJ software. Each column is themean SEM value of five independent experiments (n 5; *p
0.05, control vs 4-AP/Bic, one-way ANOVA with Bonferroni post test). E, Primary cultured cortical neurons at 10 DIV were treated with
vehicle (control), 1 mM 4-AP and 25M bicuculline (4-AP/Bic), 100M D-AP5, or 1 mM 4-aminopyridine and 25M bicuculline in the
presence of 100M D-AP5 (4-AP/BicD-AP5) for 15min followed by immunoblotting of neuronal lysates with APP Ab CT20 to detect
CTFs. Neuronal lysateswere also immunoblottedwith phospho-ERK1/ERK2 (pERK1/pERK2) and ERK1/ERK2Abs.
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ment. In addition, we found that 4-AP/
bicuculline-evoked increases in C83 levels
and phospho-ERK levels were strongly in-
hibited by the competitive selective
NMDA receptor antagonist D-AP5 (Fig.
7E).
Together, these data demonstrate that
4-AP/bicuculline treatment increases syn-
aptic activity in cultured cortical neurons
and that this increased synaptic activity
can stimulate APP cleavage and C83 CTF
production through the activation of syn-
aptic NMDA receptors.
Having established that synaptic
NMDAreceptor activity increases C83 lev-
els, we performed experiments to isolate
and activate the extrasynaptic NMDA re-
ceptor population in cultured cortical
neurons to determine whether they also
increase C83 levels. To selectively activate
extrasynaptic NMDA receptors, we first
inactivated synaptic NMDA receptors us-
ing MK801 in conjunction with 4-AP/
bicuculline treatment for 5 min. MK801 is
an open channel blocker and only binds to
activated NMDA receptors. Therefore,
NMDA receptors activated by 4-AP/bicu-
culline treatment (those at synapses) will
be blocked, whereas extrasynaptic NMDA
receptors will be left unblocked. After ex-
tensive washout of unboundMK801, bath
application of NMDA will now selectively
stimulate the extrasynaptic pool ofNMDA
receptors (synaptic NMDA receptors have
been blocked with MK801). This protocol
has previously been published by indepen-
dent laboratories (Hardingham et al.,
2002; Ivanov et al., 2006). Using this pro-
tocol, we found that bath application of
NMDA did not stimulate C83 levels (Fig.
7C, extrasynaptic protocol). Additionally,
activation of extrasynaptic NMDA recep-
tors failed to stimulate ERK1/2 phosphor-
ylation (Fig. 7C, third panel, extrasynaptic
protocol), which is in agreement with pre-
vious reports (Ivanov et al., 2006). These
data suggest that extrasynaptic NMDA re-
ceptors do not modulate -secretase-
mediated APP processing.
Figure 8. NMDA receptor activity stimulates sAPP release from primary cultured cortical neurons. A, Primary cultured cortical
neurons at 10 DIV were treated with vehicle (control) or 50M NMDA for 15, 60, and 180 min followed by immunoblotting of
samples of the neuronal culture mediumwith APP N-terminal Ab 13-M to detect secreted APP, and immunoblotting of neuronal
lysateswithAPPCT20 (cellularAPP), ERK1/ERK2,-tubulin, and synaptophysinAbs.B, Primary cultured cortical neurons at 10DIV
were treatedwith vehicle (Con) or 50MNMDA for 15, 60, and180min followedby immunoblotting of neuronal lysateswithAPP
AbCT20 to detect APPCTFs.C, Primary cultured cortical neurons at 10DIVwere treatedwith vehicle (control), 2MMK801, 50M
NMDA, or 50M NMDA in the presence of 2MMK801 (NMDAMK801) for 180min followed by immunoblotting of samples of
the neuronal culturemediumwith APPN-terminal Ab 13-M to detect secreted APP, and immunoblotting of neuronal lysateswith
APP Ab CT20 to detect cellular APP. D, sAPP levels in the neuronal culture medium under basal (control) conditions and after
treatment with NMDA for 180 min were analyzed by ECL protein band densitometry using calibrated ImageJ software. Each
column is themean SEMof four independent experiments (n 4; *p 0.05, control vs NMDA, unpaired two-tailed Student’s
4
t test). E, Primary cultured cortical neurons at 10 DIV were
treated with vehicle (control) or 50M NMDA for 15 min, 60
min, 180min, and 24 h, and then photographed under phase
contrast microscopy (320 magnification). Scale bars, 20
m. F, Primary cultured cortical neurons at 10 DIV were
treated with vehicle (control) or 50M NMDA for 15 min, 60
min, 180min, and 24 h, and the levels of LDH in the neuronal
cell culturemedium (LDH release) determined as described in
Materials andMethods. All treatmentswere performed in du-
plicate as indicated by dark gray and light gray bars.
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NMDA receptor activity stimulates sAPP release from
primary cultured cortical neurons
Cleavage of APP by -secretase produces a membrane-
embedded CTF, termed C83. At the same time, a large soluble
ectodomain fragment known as sAPP is generated, which is
secreted into the extracellular space. Our observation that
NMDA receptor activity increases the levels of C83 in neurons
suggested that activation of NMDA receptors may also increase
sAPP release. To test this, we stimulated NMDA receptors for
varying time periods followed by removal of samples of the con-
ditioned neuronal culture medium to analyze sAPP levels, which
was performed by immunoblotting. Immunoblotting was per-
formed using an APP Ab raised against a 21 aa sequence in the
N-terminal ectodomain of human APP that detects human,
mouse, and rat sAPP. We observed a single broad band running
on SDS-PAGE gels just below the 98 kDa molecular weight
marker (Fig. 8A), which corresponds to the correct molecular
weight for sAPP. It is worth noting that uncleaved full-length
APP695 runs above the 98 kDamolecular weightmarker on SDS-
PAGE gels (Fig. 3A). Furthermore, we did not detect any full-
length APP immunoreactivity in our neuronal medium samples,
as judged by immunoblotting with a C-terminally directed APP
Ab, CT20, which detects APP695 but not sAPP (data not shown).
We noticed that the basal levels of sAPP in the conditioned neu-
ronal culture medium were quite high, presumably due to accu-
mulation of sAPP with time in culture, and we were unable to
detect any significant change in sAPP levels above baseline (con-
trol) after a brief 15 min period of NMDA receptor activity (Fig.
8A). Therefore, we treated cortical cultures with NMDA for
longer time periods and found that there was a noticeable in-
crease in the levels of sAPP in the conditioned neuronal culture
medium at 60 and 180 min of NMDA treatment compared with
control (Fig. 8A). Stimulation of NMDA receptors for 180 min
produced an2-fold increase in the levels of sAPPdetected in the
neuronal culture medium (Fig. 8D). This increase mirrors the
twofold increase in C83 CTF levels that we observed after NMDA
receptor stimulation (Fig. 5F). We also found that the levels of
C83were still increased after 60 and 180min ofNMDA treatment
compared with control levels (Fig. 8B). Furthermore, we noticed
that while the levels of sAPP increased with prolonged NMDA
receptor activation, the levels of mature glycosylated cellular
APP695 appeared to decrease (Fig. 8A, second panel). This de-
crease may be the result of the increased ectodomain shedding
(sAPP release) ofmature cellular APP695 after prolongedNMDA
receptor activation. However, it has previously been reported
that prolonged NMDA receptor activity can exert neurotoxic ef-
fects on primary cultured neurons (Skaper et al., 2001), and we
also observed neurotoxicity after treatment of cortical neurons
with NMDA for 24 h (Fig. 8E,F). However, at all time points
tested here, compared with control, the levels of two major neu-
ronal proteins ERK2 and -tubulin and the synaptic marker syn-
aptophysin were not altered after NMDA treatment (Fig. 8A),
andNMDA treatment did not induce anymorphological changes
to the neuronal network (Fig. 8E), nor did it alter LDHrelease from
the neuronal cultures (Fig. 8F).
Finally, we found that the increase in sAPP release and de-
crease in cellular mature APP695 after NMDA treatment were
prevented by blocking NMDA receptors with MK801 (Fig. 8C).
Altogether, these data strongly suggest that NMDA receptor
activity increases sAPP release from primary cultured cortical
neurons.
NMDA receptor activity modulates A1-40 release from
primary cultured cortical neurons
A is produced intracellulary in vesicles by a two-step cleavage
process that involves an initial cleavage by BACE1 to produce
C89 or C99 CTFs, followed by cleavage of these CTFs by
-secretase to produce A (Vassar and Citron, 2000). A signifi-
cant proportion of the intracellular pool of A is released into the
extracellular space (Haass and Selkoe, 1993). Our results showing
that NMDA receptor activity increases -secretase-generated
C83 and sAPP release prompted us to investigate what effect
NMDA receptor activity has on A release by measuring the
levels of A1-40 in the neuronal culture medium using an
A1-40 ELISA kit that specifically detects endogenous mouse
and rat A1-40 (code no. 27720; Immuno-Biological Laborato-
ries). A release experiments were conducted over a period of 6 h
after replacing the conditioned neuronal culture medium with
fresh neurobasal medium containing vehicle or drug treatments.
Before examining the effect of NMDA receptor stimulation on
A release, to be sure that theA1-40we detected in the neuronal
culture medium was actually due to the release of A1-40 from
cortical neurons, we analyzed the levels of A1-40 in the neuro-
nal medium after treatment of neuronal cultures with the cell
permeable -secretase inhibitor DAPT. DAPT has been widely
reported to block A production and release. We found that
treatment with DAPT caused a 92% decrease in the amount of
A1-40 detected in the neuronal culturemedium compared with
control (Fig. 9A), which strongly suggests that the A1-40 we
were detecting in the neuronal culture medium was A1-40 re-
leased from cortical neurons. We then studied what effect stim-
ulation of NMDA receptors had on A1-40 release. Treatment of
cortical neurons with NMDA caused a 25% decrease in the
amount of A1-40 detected in the neuronal culture medium
compared with control, from 68.7 5.8 to 51.8 5.7 pg/ml (Fig.
9B). Furthermore, we studied what effect treatment of neuronal
cultures with NMDA had on intracellular A1-40 levels to assess
whether our observed NMDA-receptor-dependent reduction in
A1-40 release was the result of NMDA-receptor-mediated inhi-
bition of A production. We found that NMDA treatment
caused a statistically significant decrease in intracellular A1-40
levels (Fig. 9C), which suggests that NMDA receptor activity
leads to a decrease in A1-40 production. Interestingly, we also
found that treatment of cortical neurons with the NMDA recep-
tor antagonists, D-AP5 and MK801, caused a robust increase in
the amount of A1-40 detected in the neuronal culture medium
(Fig. 9D), which suggests that tonic NMDA receptor activity in
the cortical cultures modulates A1-40 release. Finally, analysis
of the neuronal cultures used for A1-40 release experiments
showed that the protein levels of APP695 and two abundant neu-
ronal proteins, ERK2 and -tubulin, were identical across exper-
imental treatments, as judged by immunoblotting (Fig. 9E),
which indicates that our observed alterations in A release were
not due to differences in cell number or drug-induced cytotoxic-
ity. Altogether, these data indicate that during periods of NMDA
receptor activity, the production and release of A1-40 is
attenuated.
NMDA receptor stimulation inhibits AICD-Gal4-driven
luciferase reporter gene activity in primary cultured cortical
neurons
A is generated from cleavage of APP by - and -secretase. We
wished to pursue an alternative experimental approach to con-
firmour ELISA data showing thatNMDA receptor activity inhib-
its A1-40 release. Therefore, we developed a cell-based reporter
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gene assay for -secretase-mediated cleavage of APP in primary
cultured cortical neurons that takes advantage of the finding that
the AICD generated after -secretase-mediated cleavage of APP
can form a tripartite transcriptionally active complex in the nu-
cleus with the APP-binding protein Fe65 and the histone acet-
lytransferase Tip60 (Cao and Su¨dhof, 2001; Cupers et al., 2001;
Gao and Pimplikar, 2001; Kimberly et al., 2001; Perkinton et al.,
2004; Konietzko et al., 2008). The assay uses a reporter APP pro-
tein consisting of human APP695 fused at its C terminus to the
yeast transcription factorGal4 containing both theDNA-binding
and activation domains (APP695-Gal4). During proteolytic pro-
cessing of exogenously expressed APP695-Gal4 by - and/or
-secretase, cleavage by -secretase at the -site produces an
AICD-Gal4 fragment that can translocate to the nucleus. Once in
the nucleus, Gal4 specifically induces transcription of a trans-
fected UAS-luciferase reporter gene (pFR-Luc) by virtue of its
transactivation domain and specific binding to a Gal4-UAS pro-
moter via its DNA-binding domain (Fig. 10A). Firefly luciferase
expression can be quantified by performing luciferase activity
assays. Thus, although this assay system ultimately relies on
translocation ofAICD to the nucleus, it does not actuallymonitor
AICD-mediated transactivation ability and functions purely as a
reporter of APP processing by secretases.
Before studying whether stimulation of NMDA receptors reg-
ulates AICD-Gal4-driven luciferase activity, we validated the re-
porter assay in primary cortical neurons. We found that cortical
neurons transfected with pFR-Luc reporter gene plasmid alone
produced a low level of basal luciferase activity, and neurons
transfected with a plasmid encoding for APP695-Gal4 had no
detectable luciferase activity (Fig. 10B). However, when cortical
neurons were cotransfected with both pFR-Luc and APP695-
Gal4 plasmids, we detected 20–25 times more luciferase activity
than neurons transfectedwith pFR-Luc plasmid alone (Fig. 10B).
Cotransfection of neurons with pFR-Luc plasmid and an
APP695-Gal4 plasmid containing a cDNA encoding for APP695-
Gal4 containing the Gal4 DNA-binding domain but lacking the
Gal4 activation domain (APP695-Gal4DBD) produced the same
level of luciferase activity as neurons transfected with pFR-Luc
plasmid alone (Fig. 10B). We verified by immunoblotting that
APP695-Gal4 and APP695-Gal4DBD fusion proteins were ex-
pressed at similar levels in cells (data not shown). These data
demonstrate that our observed firefly luciferase activity is strictly
Gal4 dependent.
It has previously been reported that the AICD is a highly
labile fragment that is stabilized when complexed with Fe65
(Kimberly et al., 2001); however, a more recent study has
shown that overexpression of Fe65 stimulates both liberation
of AICD from full-length APP and luciferase reporter gene
transcription driven by an APP-Gal4VP16 fusion protein
(Wiley et al., 2007). We examined whether Fe65 regulates
APP695-Gal4-driven luciferase activity in primary cortical
neurons and found that neurons cotransfected with plasmids
encoding for APP695-Gal4 and Fe65 produced 15–20 times
more luciferase activity than neurons transfected with
APP695-Gal4 plasmid alone (Fig. 10C).
Next, we inhibited endogenous -, -, and -secretase activ-
ities in neurons transfectedwith pFR-Luc andAPP695-Gal4 plas-
mids to determine the relative contribution of each secretase ac-
tivity toward the total luciferase activity. Treatment of cortical
neurons with the -secretase inhibitor DAPT reduced the total
luciferase activity by 85% (Fig. 10D), which suggests that the
majority of the Gal4-driven luciferase activity is dependent on
-secretase activity, as previously reported (Karlstro¨m et al.,
2002; Gianni et al., 2003; Liao et al., 2004; Zhang et al., 2007).We
obtained a similar result using an alternative -secretase inhibi-
tor, L685,458 (data not shown). The lack of complete inhibition
of luciferase activity by -secretase inhibitors has previously been
reported and discussed (Liao et al., 2004). The primary cleavage
of APP by either - or -secretase to generate C83 or C89/99
CTFs, respectively, must occur before -secretase can cleave APP
Figure 9. NMDA receptor activity modulates A1-40 release from primary cultured neurons. A, Primary cultured cortical neurons at 10 DIV were treated with vehicle (control) or 2M DAPT for
6 h, and the neuronal culturemediumwas removed and processed formeasurement of A1-40 levels using amouse/rat A1-40 ELISA kit as detailed inMaterials andMethods. Each column is the
mean SEM of four independent treatments (n 4; **p 0.01, control vs DAPT, unpaired two-tailed Student’s t test). B, Primary cultured cortical neurons at 10 DIV were treated with vehicle
(control) or 50M NMDA for 6 h, and the neuronal culturemediumwas removed and processed formeasurement of A1-40 levels using amouse/rat A1-40 ELISA kit as detailed inMaterials and
Methods. Each column is themean SEM of 18 independent treatments (n 18; *p 0.05, control vs NMDA, unpaired two-tailed Student’s t test). C, Primary cultured cortical neurons at 10 DIV
were treatedwith vehicle (control) or 50M NMDA for 6 h and processed formeasurement of intracellular A1-40 levels using amouse/rat A1-40 ELISA kit as detailed inMaterials andMethods.
Each column is themean SEMof six independent treatments (n6; *p0.05, control vsNMDA, unpaired two-tailed Student’s t test).D, Primary cultured cortical neurons at 10DIVwere treated
with vehicle (control), 100M D-AP5, or 2MMK801 for 6 h, and the neuronal culturemediumwas removed and processed formeasurement of A1-40 levels using amouse/rat A1-40 ELISA kit
as detailed inMaterials andMethods. Each column is themean SEMof nine independent treatments (n 9; **p 0.01, control vs D-AP5 and control vsMK801, one-wayANOVAwith Bonferroni
post test).E, Primary cultured cortical neurons at 10DIVwere treatedwith vehicle (control), 2MDAPT, 50MNMDA, 100M D-AP5, or 2MMK801 for 6h followedby immunoblottingof neuronal
lysates with APP CT20, ERK2 and-tubulin Abs. A single representative immunoblot is shown.
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and produce the AICD. We found that
treatment of neurons with the -secretase
(ADAM) inhibitor TAPI-1 significantly
stimulated luciferase activity, whereas
treatment of neurons with the small mol-
ecule -secretase (BACE1) inhibitor, C3,
robustly decreased luciferase activity by
60% (Fig. 10D). These results, together
with our biochemical data showing that
C3 blocks C89/99 formation and stimu-
lates C83 levels, and TAPI-1 blocks C83
formation and increases C89/C99 levels
(Fig. 3C), strongly suggest that in primary
cortical neurons the -secretase cleavage
pathway of APP preferentially mediates
AICD nuclear signaling, and also that this
assay system preferentially monitors amy-
loidogenic (A-forming) APP processing
by - and -secretase.
It has been reported that the cytoplasmic
domain of APP can be cleaved by caspases,
whichgenerates aC-terminalAPP fragment,
termedC31 (Lu et al., 2000); however, treat-
ment of cortical neurons with the broad-
spectrum caspase inhibitor, Boc-D-FMK,
did not alter the total luciferase activity (Fig.
10D), demonstrating that caspase cleavage
ofAPP-Gal4doesnot contribute to the lucif-
erase activity.
Our finding that this assay system
preferentially monitors the A-forming
pathway in neurons indicated that it
would provide the alternative experi-
mental approach that we were seeking to
validate our ELISA data showing that
NMDA receptor activity inhibits A1-40
release. Although lipid-based transfec-
tion rates in primary cultured neurons
are significantly lower than cell lines, we
were confident that the plasmids used
for monitoring -secretase-mediated
cleavage of APP would be transfected
into primary cortical neurons contain-
ing functional NMDA receptors. This as-
sumption was based on our finding that
NMDA treatment evokes phosphoryla-
tion of endogenous CREB (Ser133) in
85–90% of primary cortical neurons,
as judged by immunofluorescence (data
not shown), thus indicating that the vast
majority of primary cultured cortical
neurons contain functional NMDA re-
ceptors. In addition, we have previously
observed that treatment of primary cor-
tical neurons with NMDA robustly stim-
ulates luciferase activity arising from a
transfected CRE-luciferase reporter con-
struct (M. S. Perkinton and R. J. Wil-
liams, unpublished observations), fur-
ther indicating that the plasmids used in
the present study would be transfected
into neurons containing functional
NMDA receptors.
Figure 10. NMDA receptor stimulation inhibits AICD-Gal4-driven luciferase reporter gene activity in primary cultured cortical
neurons. A, Schematic representation of a cell-based reporter gene assay for -secretase-mediated cleavage of APP in primary
cultured cortical neurons. The assay uses a reporter APP protein consisting of human APP695 fused at its C terminus to the yeast
transcription factor Gal4. After proteolytic processing of exogenously expressedAPP695-Gal4 by-secretase and/or-secretase,
cleavage by-secretase at the-site, produces an AICD-Gal4 fragment that can translocate to the nucleus in which Gal4 induces
transcription of a transfected Gal4-dependent firefly luciferase reporter gene. Firefly luciferase expression is quantified by per-
forming a Dual-Glo luciferase activity assay as detailed in Materials and Methods. B, Primary cultured cortical neurons at 8 DIV
were transfected with pFR-Luc firefly luciferase reporter gene plasmid alone and in combination with plasmids encoding for
APP695-Gal4 or APP695-Gal4DBD. All cells were cotransfected with phRL-TK plasmid that constitutively expresses moderate
levels of Renilla luciferase. Dual-Glo luciferase activity assays were performed 24 h after transfection for quantification of firefly
and Renilla luciferase expression. Firefly luciferase reporter activity was normalized using the constitutive Renilla luciferase
activity. Each column is the mean  SEM of 12 separate transfections (n  12; **p  0.01, pFR-Luc reporter vs pFR-Luc
reporterAPP695-Gal4, one-way ANOVA with Bonferroni post test). C, Primary cultured cortical (Figure legend continues.)
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We found that treatment of primary cortical neurons with
NMDA decreased the total firefly luciferase activity when com-
pared with control activity (Fig. 10E). NMDA treatment had no
significant effect on basal luciferase activity arising from the fire-
fly luciferase reporter alone (pFR-Luc reporter: control, 194 
15.5 relative luminescence units; NMDA-treated, 185.7 13 rel-
ative luminescence units, n 56), nor did it significantly alter the
constitutive Renilla luciferase activity that was used to normalize
firefly luciferase activity (phRL-TK: control, 43,729 3256 rela-
tive luminescence units; NMDA-treated, 46,587 3173 relative
luminescence units, n  56). These results demonstrate that
NMDA treatment inhibits AICD-Gal4-driven firefly luciferase
reporter gene transcription. In addition, we found that treatment
of cortical neurons with the NMDA receptor blocker MK801
stimulated firefly luciferase activity (Fig. 10F), suggesting that
tonic endogenous NMDA receptor activity in the cortical cul-
tures reduces AICD-Gal4-driven events. The NMDA-evoked de-
crease in total firefly luciferase reporter activity was prevented
when -secretase activity was inhibited by treatment of neurons
with TAPI-1 (Fig. 10G), suggesting that -secretase activity was
required for the NMDA effect (see also Fig. 6). Finally, we found
that NMDA treatment did not inhibit AICD-Gal4-driven lucif-
erase reporter activity in cortical neurons overexpressing both
APP695-Gal4 and Fe65 (Fig. 10H).
Discussion
Nonamyloidogenic -secretase-mediated proteolytic processing
of APP is regulated by neurotransmitters and hormones, classi-
cally acting through G-protein-coupled cell surface receptors
(Mills andReiner, 1999); however, we report here that ionotropic
NMDA receptor activity enhances nonamyloidogenic APP pro-
cessing in primary cortical neurons, as illustrated by our finding
that calcium influx through NMDA receptors causes a 2- to 2.5-
fold increase in -secretase-generated C83 levels. We also report
that NMDA receptor activity increases sAPP release and de-
creases both A1-40 production and release.
A pool of APP is localized to the postsynaptic compartment in
primary cortical glutamatergic neurons
Weperformed double immunofluorescence labeling for APP and
the dendriticmarkerMAP2, for APP and synaptophysin, for APP
and the NR1 subunit, and for APP and the postsynaptic protein
PSD-95. We observed a punctate pattern of cell surface APP
staining along MAP2-positive dendrites, and at numerous sites,
APP appeared to be apposed to synaptophysin-immunoreactive
puncta. We obtained similar results when we analyzed the den-
dritic pattern of exogenously expressed APP-GFP. Furthermore,
NR1 and PSD-95 label the postsynaptic density of glutamatergic
neurons, and we observed partial overlap of APP with NR1 and
PSD-95. Together, these data indicate that APP is expressed in
primary cortical glutamatergic neurons and a pool of this APP is
trafficked to postsynaptic sites in which NMDA receptors are
expressed. The biological function of postsynaptically localized
APP remains to be determined, but we now report that its cleav-
age and metabolism may be subject to regulation by excitatory
synaptic activity (see below).
NMDA receptor activity regulates C83 CTF levels
To study regulation of the proteolytic processing of APP, we
analyzed - and -secretase-mediated APP CTF production.We
reasoned that since CTFs are the direct products of -secretase
and-secretase activity they would provide a dynamic readout of
changes in cellular APP cleavage.We characterized the pattern of
APP CTFs in primary cortical neurons using -secretase,
-secretase, and -secretase inhibitors and concluded that they
exist as a mixture of phosphorylated and nonphosphorylated
-secretase-generated C83 and -secretase-generated C89/C99
fragments. We found that brief bath application of glutamate or
NMDA to primary cortical cultures for as little as 5min increased
-CTF (C83) levels, whereas the levels of -CTF (C89) were un-
altered. NMDA-evoked increases in C83 levels were blocked by
the NMDA receptor antagonists D-AP5 and MK801 but not by
CNQX or nifedipine, were prevented by chelating extracellu-
lar calcium with EGTA, and were blocked by TAPI-1. TAPI-1
is known to be a general ADAM inhibitor, blocking a range of
ADAMs including ADAM10 and ADAM17 (Hooper et al.,
1997; Slack et al., 2001), which have been reported to be the
most likely -secretases in neurons (Buxbaum et al., 1998b;
4
(Figure legend continued.) neurons at 8 DIV were transfected with pFR-Luc firefly luciferase
reporter gene plasmid alone and in combination with plasmids encoding for APP695-Gal4 or
Fe65. All cells were cotransfectedwith phRL-TK plasmid that constitutively expressesmoderate
levels of Renilla luciferase. Dual-Glo luciferase activity assays were performed 24 h after trans-
fection for quantification of firefly and Renilla luciferase expression. Firefly luciferase reporter
activity was normalized using the constitutive Renilla luciferase activity. Each column is the
mean SEM of 12 separate transfections (n 12; **p 0.01, pFR-Luc reporterAPP695-
Gal4 vs pFR-Luc reporterAPP695-Gal4Fe65, one-wayANOVAwithBonferroni post test).D,
Primary cultured cortical neurons at 8 DIV were treated with vehicle (control), 10M DAPT, 50
MTAPI-1, 10MC3, or 20MBoc-D-FMK for 30minbefore cotransfectionwith pFR-Luc firefly
luciferase reporter gene, APP695-Gal4 and phRL-TK plasmids. Inhibitorswere present through-
out the course of the experiment. Dual-Glo luciferase activity assays were performed 24 h after
transfection for quantification of firefly and Renilla luciferase expression. Firefly luciferase re-
porter activity was normalized using the constitutive Renilla luciferase activity. Inhibitor treat-
ments did not alter the low level basal luciferase reporter activity arising from transfection of
neurons with pFR-Luc reporter gene plasmid alone (data not shown). Each column is the
mean SEM of 12 separate transfections (n 12; **p 0.01, control vs DAPT, control vs
TAPI-1 control vs C3, one-way ANOVA with Bonferroni post test). E, Primary cultured cortical
neurons at 8DIVwere cotransfectedwith pFR-Luc firefly luciferase reporter gene, APP695-Gal4,
and phRL-TK plasmids. To determine whether NMDA receptor activity altered firefly luciferase
reporter gene transcription over a 6 h time period, firefly and Renilla luciferase activity mea-
surements were made in a subset of neurons 24 h after transfection (control 0 h), and at the
same time, neurons were treated with vehicle (control) or 50M NMDA, and left for an addi-
tional 6 h followed by firefly and Renilla luciferase activity measurements. Firefly luciferase
reporter activity was normalized using the constitutive Renilla luciferase activity. This experi-
mental protocol is made possible because over the time course of the experiment, luciferase
expression is cumulative and stable. Each column is the mean SEM of 56 separate transfec-
tions (n 56; *p 0.05, control vs NMDA, unpaired two-tailed Student’s t test). F, Primary
cultured cortical neurons at 8 DIV were cotransfected with pFR-Luc firefly luciferase reporter
gene, APP695-Gal4 and phRL-TK plasmids. Twenty-four hours after transfection, neuronswere
treated with vehicle (control) or 2M MK801 for 6 h, followed by quantification of firefly and
Renilla luciferase expression by performing Dual-Glo luciferase activity assays. Firefly luciferase
reporter activitywasnormalizedusing the constitutiveRenilla luciferase activity. Each column is
themean SEM of 56 separate transfections (n 56; *p 0.05, control vsMK801, unpaired
two-tailed Student’s t test). G, Primary cultured cortical neurons at 8 DIV were cotransfected
with pFR-Luc firefly luciferase reporter gene, APP695-Gal4 and phRL-TK plasmids. Twenty-four
hours after transfection, neurons were treated with vehicle (control), 50 M TAPI-1, 50 M
NMDA, or 50M NMDA in the presence of 50M TAPI-1 (NMDATAPI-1) for 6 h, followed by
quantification of firefly and Renilla luciferase expression by performing Dual-Glo luciferase ac-
tivity assays. Firefly luciferase reporter activity was normalized using the constitutive Renilla
luciferase activity. Each column is the mean SEM of 36 separate transfections. H, Primary
cultured cortical neurons at 8 DIVwere transfectedwith pFR-Luc firefly luciferase reporter gene
plasmid in combinationwithAPP695-Gal4plasmid, orAPP695-Gal4 andFe65plasmids. All cells
were cotransfected with phRL-TK plasmid. Twenty-four hours after transfection, neurons were
treated with vehicle (control) or 50M NMDA for 6 h, followed by quantification of firefly and
Renilla luciferase expression by performing Dual-Glo luciferase activity assays. Firefly luciferase
reporter activitywasnormalizedusing the constitutiveRenilla luciferase activity. Each column is
the mean SEM of 12 (APPGal4) or 24 (APPGal4Fe65) separate transfections (*p 0.05,
APPGal4, control vs NMDA, unpaired two-tailed Student’s t test).
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Lammich et al., 1999). Thus, our CTF data strongly suggests
that a short period of NMDA receptor activity stimulates
-secretase-mediated APP cleavage.
Synaptically activated NMDA receptors are involved in
modulating APP processing
We found that increasing excitatory synaptic activity in the cor-
tical cultures, using the GABAA receptor antagonist bicuculline
and the K channel blocker 4-AP, increased C83 levels. This
stimulation protocol has been reported to selectively activate the
synaptic pool of NMDA receptors in primary cultured neurons
(Hardingham et al., 2002; Ivanov et al., 2006) and thus serves a
valuable means by which to study physiologically relevant synap-
tic NMDA receptor function in vitro. We found that 4-AP/
bicuculline-evoked increases in C83 levels were blocked by both
MK801 and D-AP5, indicating that synaptic NMDA receptors are
capable of stimulating -secretase-mediated APP cleavage and
C83 production. In contrast, we found that stimulation of extra-
synaptic NMDA receptors did not alter C83 levels.
NMDA receptor activity stimulates sAPP release
-Secretase cleaves full-length APP to produce a small
membrane-embedded C-terminal fragment, termed C83, and at
the same time a large soluble ectodomain fragment, termed
sAPP, is produced and released into the extracellular space. Our
finding that NMDA receptor activity increases C83 levels indi-
cated to us that NMDA receptor activation should also increase
sAPP release. We detected a twofold increase in the levels of
sAPP in the neuronal culture medium after treatment of cortical
neuronswithNMDA. This increase was blocked byMK801, thus,
demonstrating that NMDA receptor activity stimulates sAPP
release from cortical neurons.
NMDA receptor activity modulates-/-secretase-mediated
APP cleavage and A release
We studiedwhether our observedNMDA-receptor-mediated in-
crease in nonamyloidogenic APP cleavage impacted on amyloi-
dogenic APP processing, by measuring endogenous A1-40 pro-
duction and release fromprimary cortical neurons, andwe found
that NMDA receptor stimulation caused a significant decrease
both in A1-40 release and in intracellular A1-40 levels com-
pared with control. Furthermore, treatment of cortical neurons
with D-AP5 andMK801 increasedA1-40 release, which suggests
that tonic NMDA receptor activity in the cortical cultures regu-
lates A1-40 production.
We developed a luciferase reporter gene activity assay for
quantification of -secretase-mediated cleavage of a human
APP695-Gal4 fusion protein in cultured cortical neurons, and
demonstrated, through the use of specific -secretase and
-secretase inhibitors, that AICD-Gal4-mediated firefly lucif-
erase reporter gene transcription may be preferentially driven by
-/-secretase-mediated cleavage in neurons. It has recently been
reported that ablation of one BACE1 gene in mice strongly re-
duces AICD levels although the levels of all other APP cleavage
fragments including C83 are unchanged (Ma et al., 2007). Thus,
the-secretase cleavage pathway of APP could be a primary route
for AICD generation in neurons.
Our finding that the APP cleavage luciferase reporter assay
system preferentially monitors the A-forming pathway in cor-
tical neurons indicated to us that it would provide a useful alter-
native experimental approach to validate our ELISA data show-
ing thatNMDA receptor activity decreases A1-40 release, and as
predicted, stimulation of NMDA receptors inhibited AICD-
Gal4-driven luciferase reporter gene activity.
We also showed that coexpression of Fe65 negated the inhib-
itory effect of NMDA on AICD-Gal4-driven luciferase activity,
and this may be explained by the recent finding that overexpres-
sion of Fe65 isoforms robustly stimulates AICD levels by increas-
ing both the rate of -CTF (C83) and -CTF (C99) production
and the rate of -secretase-mediated cleavage of its immediate
substrates (C83 and C99) (Wiley et al., 2007).
In summary, our data suggests that during periods of NMDA
receptor activity, amyloidogenic (A-forming) processing ap-
pears to be reduced.
Amechanism of action for NMDA-receptor-mediated
regulation of APP processing
Our findings contrast to a previous report that NMDA receptor
activation inhibits sAPP release and stimulates A production
in primary cortical neurons (Lesne´ et al., 2005). This apparent
discrepancy may be explained by the fact that Lesne´ et al. chron-
ically stimulated NMDA receptors for 24 h before harvesting
neurons for analysis of APP fragments. Thus, it is possible that
these authors were reporting effects that were not necessarily
physiologically relevant but instead reflected a more pathophys-
iological situation, or, as the authors concluded, their observed
effects were due to transcriptional changes in the APP isoforms
expressed in the cultures after prolonged (24 h) NMDA receptor
stimulation. It is unlikely that our observed increase in C83 levels
after a 5–15 min period of synaptic NMDA receptor activity
would be due to transcriptional changes.
Recently, it has been demonstrated that synaptic activity in-
creases extracellular A levels, which may involve a change in
APP processing (Kamenetz et al., 2003), or be due to the direct
stimulation of a readily releasable pool of A present at nerve
terminals (Cirrito et al., 2005, 2008), although the involvement of
NMDA receptors was not tested. We think it is unlikely that our
data demonstrating NMDA-receptor-mediated inhibition of A
release is due to the direct modulation of a readily releasable pool
of presynaptic A. Alternatively, we propose that NMDA-
receptor-mediated inhibition of A release is a secondary event
resulting from increased-secretase-mediated cleavage ofAPP in
somatodendritic compartments. Considering that it has previ-
ously been reported that there is competition between the candi-
date -secretases ADAM10 and ADAM17 and -secretase for
APP cleavage (Skovronsky et al., 2000), an increase in
-secretase-mediated APP cleavage during NMDA receptor
stimulation could limit the amount of APP available for BACE1
cleavage, thus, attenuatingAproduction and release. In support
of our proposal, it has recently been reported that the glutamate
receptor subunit trafficking protein synapse-associated
protein-97 drives the -secretase ADAM10 to dendritic spines
upon NMDA receptor activation in primary hippocampal neu-
rons (Marcello et al., 2007).
Conclusion
Wehave studiedwhether stimulation ofNMDA receptors, which
are key molecular complexes involved in synaptic plasticity and
learning andmemory processes, influences APPmetabolism, and
our findings suggest that synaptic NMDA receptor activity pro-
motes APP processing down the nonamyloidogenic -secretase-
generated pathway, while at the same time dampening down A
production and release.
Although a pathophysiological link between AD, altered APP
processing, and NMDA receptor dysfunction has not been re-
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ported, our findings suggest that perturbation of NMDA-
receptor-dependent glutamatergic synaptic transmission by cur-
rently unknown mechanisms, could alter APP metabolism and
contribute to the rising A levels that are thought to be centrally
involved in AD. Greater understanding of the molecular mecha-
nisms by which excitatory synaptic activity regulates APP pro-
cessing may further contribute to our understanding of the
pathogenesis of AD.
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